IOP not checked

MegaPro Biomedical Co. Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Magnetic Resonance Imaging
Main trialPhase 2
“This study is an exploratory study aiming to collect data on sensitivity and positive predictive value of IOP-enhanced (MPB-1523) MRI compared to dynamic multiphase MDCT for the detection of HCC.”In the company’s words, NCT03407495 on ClinicalTrials.gov
Other names
MRI Contrast Agent

Other drugs for Magnetic Resonance Imaging

All 130 drugs for Magnetic Resonance Imaging

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Completed 30 Aug 2020 The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IOP

Following is part of Solo: you see every change to IOP the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in